Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Post by conspiTheoryon Nov 12, 2012 12:32pm
246 Views
Post# 20588991

they are still around

they are still around

From who the next step will come first, spectrum or endo?

from the transcript:

Joseph Pantginis - Roth Capital Partners, LLC, Research Division

Okay. And then just lastly, real quickly. I'm just curious if there's any updates with regard to the data analysis that were ongoing behind the scenes for apaziquone or any potential plans between you and Allergan.

Rajesh C. Shrotriya - Chairman, Chief Executive Officer, President, Chairman of Placement Committee and Chairman of Product Acquisition Committee

Yes. So I think as we have said before, Joe, that we have -- we are planning to have a meeting with the FDA sometime in the future and see what strategy we can develop. As you know, that when the 2 studies are combined, then the data is highly significant in favor of apaziquone. However, standalone 2 studies do not make the feedback view of less than 05. So at this time, this is work in progress, and we'll keep you posted.

https://seekingalpha.com/article/988451-spectrum-pharmaceuticals-management-discusses-q3-2012-results-earnings-call-transcript?part=single

Bullboard Posts